Winway Health Desk
Digital Health’s ROI Reckoning: How To Uncover New Value From Old...
Tired of their digital health spend not delivering on ROI as promised, many healthcare system CFOs have made their expectations clear: any new technology...
FDA Approves Roche Lymphoma Drug, Bringing Competition to New AbbVie Med
A new Roche drug for blood cancer has won FDA approval, bringing patients another therapeutic option and one that will compete against a recently...
Here Are ChatGPT’s Limitations Compared to Specialized AI Chatbots in Symptom...
AI is transforming the way we perceive and manage our healthcare system. From its potential to provide decision support for healthcare professionals to assisting...
Providence Scales Back Services in Oregon to Prep for Nurses’ Strike
Providence is cutting back on services at three of its Oregon facilities to brace for an upcoming nurses’ union strike. The 51-hospital health system...
Valley Children’s Healthcare To Install Microgrid On California Hospital Campus
Located in a rural part of Central California, Valley Children’s Healthcare, which delivers care to more than 1.3 million children, regularly faces the threat...
10 New Artwork And Wayfinding Products
New healthcare artwork and wayfinding products
From custom-painted murals and mosaics to acoustic artwork, vendors and manufacturers are introducing a range of new artwork and...
Page Completes Integration With EYP
Washington, D.C.-based Page, a multidisciplinary design, architecture, and engineering firm, has completed its integration of architectural firm EYP (Albany, N.Y.). Page acquired the firm...
Pharma Injecting Life into Digital Health Amidst Funding Downturn
The consensus is 2022 was a challenging year for digital health companies. Venture capital and other startup investment in the U.S. digital health sector...
12 Common Muscle-Building Mistakes – Breaking Muscle
The ability to build muscle in response to training is a part of our physiology. It’s deeply encoded in our DNA and persists throughout...
FDA Approves Columvi (glofitamab-gxbm) Bispecific Antibody for the Treatment of Relapsed...
FDA Approves Columvi (glofitamab-gxbm) Bispecific Antibody for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaSouth San Francisco, CA -- June 15, 2023...
